In court documents he is identified only as doctor No. 2. But sources say that it was a prominent and trusted New Jersey doctor and Alzheimer's researcher for an Elan drug candidate who was the second tell-all source for an alleged massive insider trading deal, one of a number of cases authorities are pursuing.
A so-called superseding federal indictment today says former hedge fund trader Mathew Martoma, accused of insider trading in Elan and Wyeth stock, had not one but two doctors giving him the inside scoop that allowed his hedge fund to record more than $275 million in profits and losses avoided.
PricewaterhouseCoopers has been running the numbers on deals and dollars in the biopharma industry. And the big accounting firm is echoing a growing lineup of analysts who see that dealmaking in the industry is suffering even as IPOs are booming. But easy access to cash could change things around dramatically in the second half of this year.
Looking over the 416 licensing deals EvaluatePharma tracked for the first six months of the year, total upfronts and deal values for Phase II programs were well ahead of Phase III--as well as the pace set for mid-stage pacts in the first half of 2012.
For some pharma dealmakers, corporate domiciles in Ireland have become hot commodities. The Irish tax code figured prominently in two recent biopharma buyout deals, and, as Bloomberg reports, this makes the biotech group Alkermes and Jazz Pharmaceuticals potential targets.
Perrigo has snatched up Elan for $8.6 billion in a cash-and-stock deal. Call it a case of opposites attracting: U.S.-based Perrigo specializes in cheap, store-brand generics, while Elan is an Irish biotech best know for its longstanding--and now dissolved--partnership with Biogen Idec on the multiple sclerosis drug Tysabri.
The chase for Elan appears to be over. Perrigo, a U.S. maker of over-the-counter and generic drugs, has emerged with a winning bid to acquire the Irish biotech outfit for $8.6 billion in cash and stock.
Allergan and Forest Laboratories are still in the hunt for Elan. The Irish drugmaker is looking for formal first-round bids this week, sources tell Reuters, after opening a formal sale process last month.
In the latest twist in Royalty Pharma's plot to buy Elan, the business press has caught wind that Royalty may decide to revive its pursuit of Elan with the help and financial support of a partner. This scenario involves multiple factors, including Elan's willingness to take offers from joint bidders, and none of the players is commenting on the record about the situation.
Elan shareholders didn't much care for Kelly Martin's $1 billion royalty deal with Theravance. Or any other deals, for that matter, aside from a share buyback. But that doesn't seem to upset Theravance CEO Rick Winningham even a little bit.